Sirolimus-Coated Balloon Proves Equivalent to Stenting in Cardiovascular Procedures
Groundbreaking Results from the TRANSFORM II Trial
In a major clinical breakthrough, the TRANSFORM II trial has demonstrated that the use of the MagicTouch Sirolimus-Coated Balloon (SCB) is non-inferior to everolimus-eluting stents (EES) when it comes to treating patients with de novo coronary artery disease. This pivotal study was unveiled during the TCT 2026 conference and has been accepted for publication in The Lancet, shedding light on the future of interventional cardiology treatment strategies.
Overview of the TRANSFORM II Trial
The TRANSFORM II trial is a robust open-label study that involved 1,842 patients across 53 centers in 11 countries including regions from Europe, Asia, and South America. The goal was to compare the efficacy and safety of the MagicTouch SCB against traditional EES. Patients enrolled in this trial had a unique set of challenges; they presented with complex conditions often marked by acute coronary syndromes, diabetes, and a high risk of bleeding complications.
Participants were randomly assigned to receive either the SCB or EES after a successful preparation of the lesion, a critical aspect that underpins the trial's outcomes. The main focus was on Target Lesion Failure (TLF), defined as a combination of cardiac death, target-vessel myocardial infarction, and the need for further surgical intervention. This means that patients could experience the same therapeutic benefits without the long-term ramifications associated with permanent stenting.
Impressive Outcomes
After one year, the incidence of TLF was recorded at 2.1% for the SCB group compared to 2.4% in the EES group. This indicates a promising hazard ratio of 0.86, along with a strong non-inferiority conclusion that supports the use of SCB as a feasible option (p=0.004). Even more encouraging was the fact that complications such as adverse clinical events were notably lower in the SCB arm, at 4.1% versus 5.3% for EES.
One of the standout features of this trial was the remarkably lower necessity for bailout stenting, which occurred in only 7.6% of patients receiving the SCB, juxtaposed against historical data where this figure was considerably higher due to the timing of randomization prior to lesion preparation.
Insights and Future Directions
Dr. Bernardo Cortese, principal investigator of the study, emphasized that these findings highlight the potential of drug-coated balloon therapy not merely as a device alternative but as a comprehensive strategy that requires meticulous lesion preparation and the readiness to opt for stenting when necessary. He noted this study serves as
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.